Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it will host ...

Humacyte (NASDAQ:HUMA) outlined the unmet need in hemodialysis vascular access and highlighted data from its clinical program ...

Industry veteran with more than 25 years of experience will lead next phase of biotech company’s commercial expansion –– Seasoned medtech ...

Humacyte, Inc. (HUMA) closed at $0.70 in the latest trading session, marking a -1.14% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.8%. Meanwhile, the Dow ...

DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed ...

Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients April 28, 2026 8:00 AM ...

On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...

(RTTNews) - Humacyte, Inc. (HUMA) has launched Symvess, a bioengineered vascular conduit for adults needing urgent revascularization due to extremity arterial injury when autologous vein grafts aren't ...

DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial ...

On April 21, 2026, Humacyte entered a third amendment to its distribution agreement with Fresenius Medical Care, regaining sole global rights to develop, commercialize and manage regulatory matters ...